JP6674375B2 - 臨床転帰トラッキング及び分析 - Google Patents
臨床転帰トラッキング及び分析 Download PDFInfo
- Publication number
- JP6674375B2 JP6674375B2 JP2016521623A JP2016521623A JP6674375B2 JP 6674375 B2 JP6674375 B2 JP 6674375B2 JP 2016521623 A JP2016521623 A JP 2016521623A JP 2016521623 A JP2016521623 A JP 2016521623A JP 6674375 B2 JP6674375 B2 JP 6674375B2
- Authority
- JP
- Japan
- Prior art keywords
- clinical
- patient
- patients
- clinical outcome
- clinically relevant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004458 analytical method Methods 0.000 title claims description 51
- 238000011282 treatment Methods 0.000 claims description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 84
- 201000010099 disease Diseases 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 47
- 229940079593 drug Drugs 0.000 claims description 43
- 230000004083 survival effect Effects 0.000 claims description 35
- 230000036541 health Effects 0.000 claims description 34
- 238000003745 diagnosis Methods 0.000 claims description 22
- 231100000419 toxicity Toxicity 0.000 claims description 21
- 230000001988 toxicity Effects 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 7
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000000391 smoking effect Effects 0.000 claims description 5
- 238000012384 transportation and delivery Methods 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000012937 correction Methods 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 230000003116 impacting effect Effects 0.000 claims 2
- 238000003860 storage Methods 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 208000026310 Breast neoplasm Diseases 0.000 description 20
- 238000012545 processing Methods 0.000 description 20
- 206010006187 Breast cancer Diseases 0.000 description 19
- 238000010586 diagram Methods 0.000 description 18
- 238000004891 communication Methods 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 238000012216 screening Methods 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 230000002085 persistent effect Effects 0.000 description 8
- 206010061818 Disease progression Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101150105104 Kras gene Proteins 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- APTZNLHMIGJTEW-UHFFFAOYSA-N pyraflufen-ethyl Chemical compound C1=C(Cl)C(OCC(=O)OCC)=CC(C=2C(=C(OC(F)F)N(C)N=2)Cl)=C1F APTZNLHMIGJTEW-UHFFFAOYSA-N 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 108091005515 EGF module-containing mucin-like hormone receptors Proteins 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100035348 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002079 electron magnetic resonance spectroscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/28—Databases characterised by their database models, e.g. relational or object models
- G06F16/284—Relational databases
- G06F16/285—Clustering or classification
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/90—Details of database functions independent of the retrieved data types
- G06F16/901—Indexing; Data structures therefor; Storage structures
- G06F16/9024—Graphs; Linked lists
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/90—Details of database functions independent of the retrieved data types
- G06F16/95—Retrieval from the web
- G06F16/953—Querying, e.g. by the use of web search engines
- G06F16/9535—Search customisation based on user profiles and personalisation
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation; Time management
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0201—Market modelling; Market analysis; Collecting market data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
Landscapes
- Engineering & Computer Science (AREA)
- Business, Economics & Management (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Databases & Information Systems (AREA)
- Strategic Management (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Human Resources & Organizations (AREA)
- Entrepreneurship & Innovation (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Development Economics (AREA)
- General Business, Economics & Management (AREA)
- Economics (AREA)
- Finance (AREA)
- Accounting & Taxation (AREA)
- Marketing (AREA)
- Game Theory and Decision Science (AREA)
- Educational Administration (AREA)
- General Engineering & Computer Science (AREA)
- Operations Research (AREA)
- Quality & Reliability (AREA)
- Tourism & Hospitality (AREA)
- Pathology (AREA)
- Software Systems (AREA)
- Bioethics (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888418P | 2013-10-08 | 2013-10-08 | |
| US61/888,418 | 2013-10-08 | ||
| PCT/US2014/059354 WO2015054156A1 (en) | 2013-10-08 | 2014-10-06 | Clinical outcome tracking and analysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502365A JP2017502365A (ja) | 2017-01-19 |
| JP6674375B2 true JP6674375B2 (ja) | 2020-04-01 |
Family
ID=52777665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521623A Active JP6674375B2 (ja) | 2013-10-08 | 2014-10-06 | 臨床転帰トラッキング及び分析 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20150100341A1 (ko) |
| EP (1) | EP3055803B1 (ko) |
| JP (1) | JP6674375B2 (ko) |
| KR (2) | KR102119790B1 (ko) |
| CN (1) | CN105793856A (ko) |
| BR (1) | BR112016007630A2 (ko) |
| CA (2) | CA3210162A1 (ko) |
| DK (1) | DK3055803T3 (ko) |
| ES (1) | ES2908089T3 (ko) |
| HK (1) | HK1225464A1 (ko) |
| IL (1) | IL244852B (ko) |
| MX (1) | MX2016004380A (ko) |
| PL (1) | PL3055803T3 (ko) |
| PT (1) | PT3055803T (ko) |
| WO (1) | WO2015054156A1 (ko) |
| ZA (3) | ZA201602303B (ko) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130124217A1 (en) * | 2011-11-11 | 2013-05-16 | Debra Thesman | Health plan rating system improvement program |
| US20140336943A1 (en) * | 2013-01-05 | 2014-11-13 | Foundation Medicine, Inc. | System and method for managing genomic testing results |
| US11985075B1 (en) | 2013-02-04 | 2024-05-14 | C/Hca, Inc. | Data stream processing for dynamic resource scheduling |
| WO2015081086A1 (en) * | 2013-11-27 | 2015-06-04 | The Johns Hopkins University | System and method for medical data analysis and sharing |
| US20150350040A1 (en) * | 2014-06-02 | 2015-12-03 | Hcl Technologies Ltd. | Enabling an early response to a disease based on data analytics |
| US11182459B1 (en) * | 2014-09-26 | 2021-11-23 | Sentry Data Systems, Inc. | Automated comparative healthcare, financial, operational, and quality outcomes and performance benchmarking |
| US20180268937A1 (en) * | 2015-09-24 | 2018-09-20 | Caris Science, Inc. | Method, apparatus, and computer program product for analyzing biological data |
| US10698078B2 (en) | 2015-12-07 | 2020-06-30 | Cvs Pharmacy, Inc. | Clinic wait-time visibility and reservations |
| US11165722B2 (en) | 2016-06-29 | 2021-11-02 | International Business Machines Corporation | Cognitive messaging with dynamically changing inputs |
| WO2018044894A1 (en) * | 2016-08-29 | 2018-03-08 | Chen James C | Connected systems, devices, and methods for monitoring clinical treatments |
| US10878962B2 (en) * | 2016-11-02 | 2020-12-29 | COTA, Inc. | System and method for extracting oncological information of prognostic significance from natural language |
| CN110168659A (zh) * | 2016-11-14 | 2019-08-23 | 科塔公司 | 用于改善临床结果并降低总护理费用的cna引导的护理 |
| US10529446B2 (en) | 2016-12-22 | 2020-01-07 | International Business Machines Corporation | Continuous health care plan coordination between patient and patient care team |
| WO2018183470A1 (en) * | 2017-03-28 | 2018-10-04 | Bruce Ramshaw | Performing predictive patient care options that improve value based on historical data |
| US20180293352A1 (en) * | 2017-04-10 | 2018-10-11 | COTA, Inc. | System and Method for Decision-Making for Determining Initiation and Type of Treatment for Patients with a Progressive Illness |
| CN111742370A (zh) * | 2017-05-12 | 2020-10-02 | 密歇根大学董事会 | 个体和队列药理学表型预测平台 |
| WO2018222898A1 (en) * | 2017-06-02 | 2018-12-06 | Mayo Foundation For Medical Education And Research | System and method for providing clinical outcomes driven expertise for disease treatment |
| US11562143B2 (en) | 2017-06-30 | 2023-01-24 | Accenture Global Solutions Limited | Artificial intelligence (AI) based document processor |
| US10489502B2 (en) | 2017-06-30 | 2019-11-26 | Accenture Global Solutions Limited | Document processing |
| US11003796B2 (en) | 2017-06-30 | 2021-05-11 | Accenture Global Solutions Limited | Artificial intelligence based document processor |
| US20190096017A1 (en) * | 2017-09-25 | 2019-03-28 | General Electric Company | Medical procedure cost evaluation and optimization |
| IL255255A0 (en) * | 2017-10-25 | 2017-12-31 | Optimata Ltd | A system and method for predicting the effect of medical treatment |
| US11610688B2 (en) | 2018-05-01 | 2023-03-21 | Merative Us L.P. | Generating personalized treatment options using precision cohorts and data driven models |
| KR102192164B1 (ko) * | 2018-08-08 | 2020-12-16 | 주식회사 딥바이오 | 생체 이미지 진단 시스템, 생체 이미지 진단 방법, 및 이를 수행하기 위한 단말 |
| US11636949B2 (en) * | 2018-08-10 | 2023-04-25 | Kahun Medical Ltd. | Hybrid knowledge graph for healthcare applications |
| US11515018B2 (en) | 2018-11-08 | 2022-11-29 | Express Scripts Strategic Development, Inc. | Systems and methods for patient record matching |
| US11562257B2 (en) | 2018-11-28 | 2023-01-24 | Merative Us L.P. | Identifying knowledge gaps utilizing cognitive network meta-analysis |
| CN109801172B (zh) * | 2018-12-14 | 2023-08-29 | 中国平安财产保险股份有限公司 | 基于数据分析的患者跟踪管控方法、装置和计算机设备 |
| CN109814502B (zh) * | 2019-01-11 | 2021-08-06 | 广东中烟工业有限责任公司 | 一种制丝原料配方防错方法及装置 |
| US11816619B2 (en) * | 2019-04-26 | 2023-11-14 | The Dedham Group Llc | Third party program transparency tool |
| KR102272401B1 (ko) * | 2019-08-02 | 2021-07-02 | 사회복지법인 삼성생명공익재단 | 의료 데이터 웨어하우스 실시간 자동 업데이트 시스템, 방법 및 이의 기록매체 |
| US20220344013A1 (en) * | 2019-10-02 | 2022-10-27 | Endpoint Health Inc. | Directing Medical Diagnosis and Intervention Recommendations |
| CN110893006A (zh) * | 2019-12-11 | 2020-03-20 | 河南中烟工业有限责任公司 | 一种基于信息化平台的卷烟批次质量信息精准追溯方法 |
| CN112992302A (zh) * | 2019-12-12 | 2021-06-18 | 阿里巴巴集团控股有限公司 | 数据处理方法、装置、设备和存储介质 |
| KR20230107914A (ko) * | 2020-02-26 | 2023-07-18 | 브라이트 클리니컬 리서치 리미티드 | 진행중인 임상 시험을 동적으로 모니터링하고 지도하기위한 레이더 시스템 |
| US20210272662A1 (en) * | 2020-02-27 | 2021-09-02 | Lawrence German | Application, system, and method for a computer implemented medical electronic record management system |
| KR102371037B1 (ko) * | 2020-08-18 | 2022-03-07 | 서울대학교병원 | 프로그래밍이 가능한 전자의무기록 시스템 |
| KR102335483B1 (ko) * | 2021-01-05 | 2021-12-06 | 서울대학교병원 | 임상시험 안전성 관리 방법 및 장치 |
| IL280496A (en) * | 2021-01-28 | 2022-08-01 | Yeda Res & Dev | Artificial intelligence for predicting laboratory test results |
| KR102632155B1 (ko) * | 2021-03-16 | 2024-01-31 | 재단법인 아산사회복지재단 | 의료 데이터에 기초한 코호트 데이터 처리 장치 및 방법 |
| CN113380358B (zh) * | 2021-06-01 | 2022-12-16 | 上海德衡数据科技有限公司 | 基于物联网的医疗信息交互的方法、装置及设备 |
| KR102503195B1 (ko) * | 2021-11-09 | 2023-02-23 | 주식회사 에이치엠씨네트웍스 | 환자의 전원 정보에 대응되는 병원 정보를 노출하는 방법 및 그 장치 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7353238B1 (en) * | 1998-06-12 | 2008-04-01 | Outcome Sciences, Inc. | Apparatus and methods for determining and processing medical outcomes |
| AU2612700A (en) * | 1999-01-14 | 2000-08-01 | Point Loma Industries, Inc. | Expert system for converting data records from a table-based format to a data tree format |
| US8369937B2 (en) * | 1999-11-16 | 2013-02-05 | Cardiac Pacemakers, Inc. | System and method for prioritizing medical conditions |
| AU2002211304A1 (en) * | 2000-09-29 | 2002-04-08 | New Health Sciences, Inc. | Systems and methods for assessing vascular effects of a treatment |
| JP3823192B2 (ja) * | 2002-04-19 | 2006-09-20 | 学校法人慶應義塾 | 診療支援装置、診療支援方法、及び診療支援プログラム |
| JP2004133826A (ja) * | 2002-10-15 | 2004-04-30 | Hitachi Ltd | 電子カルテシステム |
| US7774377B2 (en) * | 2003-12-03 | 2010-08-10 | The Trizetto Group, Inc. | Range definition method and system |
| JP2005223629A (ja) | 2004-02-05 | 2005-08-18 | Asahi Kasei Corp | 携帯電子機器 |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF PATIENTS OF BREAST CANCER USING A COMBINATION OF CLINICAL CRITERIA AND GENETIC INFORMATIVE SETS |
| JP4619219B2 (ja) * | 2005-07-19 | 2011-01-26 | 株式会社エヌ・ティ・ティ・データ | 被験者選定装置 |
| RU2008110491A (ru) * | 2005-08-19 | 2009-09-27 | Конинклейке Филипс Электроникс Н.В. (Nl) | Система управления данными здравоохранения |
| US7805385B2 (en) | 2006-04-17 | 2010-09-28 | Siemens Medical Solutions Usa, Inc. | Prognosis modeling from literature and other sources |
| US20080091472A1 (en) * | 2006-10-11 | 2008-04-17 | Steven Hoppe | Treatment monitoring tool |
| EP2211687A4 (en) | 2007-10-12 | 2013-08-21 | Patientslikeme Inc | PERSONALIZED MANAGEMENT AND SURVEILLANCE OF PATHOLOGICAL CONDITIONS |
| KR101806432B1 (ko) * | 2008-03-26 | 2017-12-07 | 테라노스, 인코포레이티드 | 임상 결과를 평가하기 위한 방법 및 시스템 |
| BRPI0914079A2 (pt) * | 2008-10-10 | 2015-10-27 | Cardiovascular Decision Technologies Inc | "método e sistema para avaliar dados médicos, meio de armazenamento e método para adicionar e modificar um conjunto de características candidato relacionado a uma condição médica" |
| US20120130737A1 (en) * | 2009-09-17 | 2012-05-24 | Therapeuticsmd, Inc. | System and method for distrubutor reporting and analysis |
| KR20110066576A (ko) * | 2009-12-11 | 2011-06-17 | 서울대학교병원 | 임상시험 및 임상연구용 의료 정보관리 시스템 및 방법 |
| US20120029939A1 (en) * | 2010-07-30 | 2012-02-02 | General Electric Company | Methods and apparatus to group and present clinical records |
| US20120166218A1 (en) | 2010-12-27 | 2012-06-28 | Bruce Reiner | Method and system of real-time customizable medical search analytics |
| WO2012145616A2 (en) * | 2011-04-20 | 2012-10-26 | The Cleveland Clinic Foundation | Predictive modeling |
| EP2795495B1 (en) * | 2011-12-21 | 2019-09-04 | Koninklijke Philips N.V. | Method and system to predict physiologic and clinical status changes |
| US20130226612A1 (en) * | 2012-02-26 | 2013-08-29 | International Business Machines Corporation | Framework for evidence based case structuring |
| US20140006044A1 (en) * | 2012-06-27 | 2014-01-02 | Infosys Limited | System and method for preparing healthcare service bundles |
| IN2013CH00818A (ko) | 2013-02-25 | 2015-08-14 | Cognizant Technology Solutions India Pvt Ltd |
-
2014
- 2014-10-06 CA CA3210162A patent/CA3210162A1/en active Pending
- 2014-10-06 PT PT148518277T patent/PT3055803T/pt unknown
- 2014-10-06 EP EP14851827.7A patent/EP3055803B1/en active Active
- 2014-10-06 CA CA2926703A patent/CA2926703C/en active Active
- 2014-10-06 DK DK14851827.7T patent/DK3055803T3/da active
- 2014-10-06 KR KR1020187006089A patent/KR102119790B1/ko active IP Right Grant
- 2014-10-06 WO PCT/US2014/059354 patent/WO2015054156A1/en active Application Filing
- 2014-10-06 MX MX2016004380A patent/MX2016004380A/es unknown
- 2014-10-06 KR KR1020167012011A patent/KR101835880B1/ko active Search and Examination
- 2014-10-06 BR BR112016007630A patent/BR112016007630A2/pt unknown
- 2014-10-06 PL PL14851827T patent/PL3055803T3/pl unknown
- 2014-10-06 US US14/507,640 patent/US20150100341A1/en not_active Abandoned
- 2014-10-06 ES ES14851827T patent/ES2908089T3/es active Active
- 2014-10-06 JP JP2016521623A patent/JP6674375B2/ja active Active
- 2014-10-06 CN CN201480067169.7A patent/CN105793856A/zh active Pending
-
2015
- 2015-01-12 US US14/594,969 patent/US9378531B2/en active Active
-
2016
- 2016-03-31 IL IL244852A patent/IL244852B/en active IP Right Grant
- 2016-04-06 ZA ZA2016/02303A patent/ZA201602303B/en unknown
- 2016-08-10 US US15/233,564 patent/US9734289B2/en active Active
- 2016-08-10 US US15/233,548 patent/US9734288B2/en active Active
- 2016-08-23 ZA ZA2016/05844A patent/ZA201605844B/en unknown
- 2016-08-23 ZA ZA2016/05843A patent/ZA201605843B/en unknown
- 2016-12-01 HK HK16113683A patent/HK1225464A1/zh unknown
-
2018
- 2018-02-12 US US15/894,618 patent/US10902953B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6674375B2 (ja) | 臨床転帰トラッキング及び分析 | |
| Menachemi et al. | The benefits of health information exchange: an updated systematic review | |
| US9646135B2 (en) | Clinical outcome tracking and analysis | |
| US9734291B2 (en) | CNA-guided care for improving clinical outcomes and decreasing total cost of care | |
| JP7355415B2 (ja) | 臨床転帰を改善し、総治療費を低減するためのｃｎａガイドケア | |
| US20210343420A1 (en) | Systems and methods for providing accurate patient data corresponding with progression milestones for providing treatment options and outcome tracking | |
| Goldie | Chapter 15: Public health policy and cost-effectiveness analysis | |
| US20210082573A1 (en) | Clinical outcome tracking and analysis systems and methods employing provisional nodal addresses relevant to treatment and refined nodal addresses relevant to prognosis-related expected outcome and risk assessment | |
| WO2023287920A9 (en) | Systems and methods for providing accurate patient data corresponding with progression milestones for providing treatment options and outcome tracking |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170201 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180905 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200123 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200128 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200206 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200306 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6674375 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |